RenovaCare, Inc. operates as a development stage company, which engages in the research, development, and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company is headquartered in Scottsdale, Arizona and currently employs 1 full-time employees. The company went IPO on 2000-08-08. The firm is focused on the research, development and commercialization of autologous cellular therapies for the regeneration of human organs and tissues. The Company’s product under development targets the skin. The firm's flagship technology, the CellMist System, renders single-cell suspensions of tissue-specific pluripotent cells from donor tissues through sequential protease digestions. The RenovaCare CellMist System facilitates healing of wounds or other afflicted tissues when applied as a gentle cell mist using the RenovaCare SkinGun. The Company’s CellMist System consists of the CellMist cell suspension derived by enzymatic digestion of a patient’s own skin tissue applied topically with its electronic SkinGun spray device to deliver a single-cell mist onto the patient's burn wound. The firm's wholly owned subsidiary is RenovaCare Sciences Corp.